Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer

King, Madeleine; Stockler, Martin R.; Butow, Phyllis; O’Connell, Rachel; Voysey, Merryn; Oza, Amit M.; Gillies, Kim; Donovan, Heidi S.; Mercieca-Bebber, Rebecca; Martyn, Julie; Sjoquist, Katrin Marie; Friedlander, Michael

doi:10.1097/igc.0000000000000167

Cited by 31 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quality of life (QOL) and other patient-reported outcomes (PROs) are important endpoints in ovarian cancer randomised controlled trials (RCTs), as the disease and its treatment can result in significant morbidities [1]. PROs are particularly important in patients with recurrent ovarian cancer where survival time is relatively short [1]. The average five-year survival rate for ovarian cancer is approximately 44-46% and there has been very little improvement in survival over the past 30 years [2,3].…”

Section: Discussionmentioning

confidence: 99%

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moving forward, a new patient‐reported outcome measure—Measure of Ovarian Symptoms and Treatment—has been developed and validated in an effort by the Gynecological Cancer InterGroup (GCIG) to include a measure of symptom burden and symptom benefit in trials of palliative chemotherapy in patients with recurrent ovarian cancer , and we expect that it will be used in future GCIG clinical trials. The Aide et Recherche en Cancérologie Digestive group (ARCAD) are currently developing “PRO‐Response Evaluation Criteria In Solid Tumors” criteria to use as co–primary endpoints in trials in patients with recurrent colon cancer and pancreatic cancer .…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve

et al. 2017

Self Cite

View full text Add to dashboard Cite

The impact of treatment on quality of life (QOL) is an important consideration in patients with ovarian cancer for whom treatment is often given with palliative intent. Both the disease and treatment impact a patient's QOL and require careful evaluation in clinical trials. Matching the QOL questions to the patient population of interest is critical. Similar rigor to that used to assess progression-based endpoints is essential to guide clinical decisions. This systematic review demonstrated that although the inclusion and reporting of QOL as a trial endpoint has improved in phase III trials there are still significant shortfalls that need to be addressed in future trials.

show abstract

“…Recently published data has not reported significant impact on early treatment discontinuation of chemotherapy in cohort of 1213 patients with relapsed ovarian cancer [35]. Although only some physical and emotional domains of quality of life were described most salient, there is no prospective evaluation in ovarian cancer patients and distinct domains are more than heterogeneous [36, 37]. Exemplarily patients after extensive tumour debulking with gross bowel resection, who are not able to resorb oral drugs due to consequently insufficient bowel metabolism, needs quite different treatment strategy as an elderly and frail patient with accumulated gastrointestinal toxicity [35, 38].…”

Section: Discussionmentioning

confidence: 99%

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Chekerov

Harter

Fuxius

et al. 2017

gynaecol oncol res pract

View full text Add to dashboard Cite

BackgroundPalliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints.MethodsPatients with ROC had the free choice between treosulfan i.v. (7000 mg/m2 d1, q29d) or p.o. (600 mg/m2 daily d1-28, q57d). Only indecisive participants were randomized.ResultsOverall 123 patients with 2nd to 5th recurrence were registered and 119 received at least one cycle of chemotherapy. 85.7% preferred treosulfan i.v. and 14.3% oral, where only three patients were randomized. Main reasons for i.v. preference associated with individual expectations of lower rate of gastrointestinal disorders, higher activity and tolerability of treatment. Median of applied chemotherapies was three (range 1–12 cycles), with most common grade 3/4 toxicities thrombopenia (18.7%), leukopenia (15.7%), ascites (7.6%), bowel obstruction (6.7%), and abdominal pain (4.2%). Median time until progression/overall survival was 5.2/7.8 months (i.v.), and 5.6/10.4 months (p.o.), respectively, without significant differences in efficacy.ConclusionsElderly patients with recurrent ovarian cancer asked and demonstrated active participation in the decision-making process of their oncological treatment and favoured predominantly the i.v. application. Treosulfan was generally well-tolerated despite comorbidities and heavy pre-treatment. Our study demonstrates that patients’ preference did not influence prognosis negatively and remains important in gynaecologic oncology decision practice.EudraCT Nr.2004-000719-25; NCT 00170690

show abstract

Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer

Cited by 31 publications

References 24 publications

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Contact Info

Product

Resources

About